Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06141434 · ClinicalTrials.gov registry record
PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life
A clinical trial of Type 1 Diabetes and Pregnancy in Diabetic, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 6,000
- Enrollment target
- 4
- Study locations
NCT06141434 is a study of Type 1 Diabetes and Pregnancy in Diabetic that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 6,000 participants, above the 791-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (659% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT06141434, a study of Type 1 Diabetes and Pregnancy in Diabetic, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is called 'PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life: The PROMISE Study'. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of type 1 diabetes (TID) and islet autoimmunity in the child. We are also interested in finding out more about why having a father or sibling with T1D increases risk of autoimmunity in the child more than having a mother with T1D. We are enrolling women who are pregnant and either have T1D or another first degree relative (father or full sibling) of the baby has T1D. The biological father is also invited to enroll in study, as it is important to understand how the father's health and genetics may contribute to the child's risk of developing T1D. The study procedures for the mother, father and baby are explained below. Mother: Pregnant women will be asked to complete a visit once per trimester (3 visits) during pregnancy and one visit up to 12 weeks after delivery. At each visit, mothers will consent to a blood draw, collection of biological samples and the completion of questionnaires. . Mothers who have T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data. Father: The (biological) father will be invited to enroll in a single visit. He will consent to a blood draw and completion of questionnaires. Fathers with T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data. Baby: The baby will have blood collected at birth to determine the genetic risk for T1D. Families will consent to the completion of questionnaires about growth, health and diet at 6, 12, 18 and 24 months of age and between 5-7 years of age, and to complete blood testing for islet autoantibodies at 24 months and between 5-7 years of age. For those children with a high genetic risk
Conditions Studied
Study Locations (4)
Colorado
- University of Colorado - Aurora
Massachusetts
- Joslin Diabetes Center - Boston
New York
- Mt Sinai - New York
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2032-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06141434
The ClinicalTrials.gov registry entry for NCT06141434 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 791-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (659% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 0 interventions.
NCT06141434 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06141434 about?
NCT06141434 is a clinical study titled "PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life". This research study is called 'PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life: The PROMISE Study'. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of type 1 diabet...
What is the current status of trial NCT06141434?
This trial is currently recruiting. The enrollment target is 6,000 participants. The study started on 2022-12-01. Estimated completion is 2032-11-30.
What conditions does trial NCT06141434 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Pregnancy in Diabetic.
Who is sponsoring clinical trial NCT06141434?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06141434 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.